Dr. Berta Strulovici received her Ph.D from The Weizmann Institute of Science in Rehovot, Israel. She then conducted postdoctoral research under the guidance of Professor Robert J. Lefkowitz at the Howard Hughes Medical Institute Duke University Medical School in Durham, NC, USA. Berta has a track record in building and leading outstanding, productive teams, while integrating innovative processes into seamless, successful enterprises in start-up and large Pharma environments. At Merck Sharpe and Dohme in North Wales, PA, Berta was Vice President of Basic Research in charge of building a state-of-the-art Center of Excellence for early drug discovery for Merck Worldwide. She was involved in the discovery of lead compounds that are currently in clinical trials for various diseases. About 3 years ago, Berta joined a new start up biotech, iPierian, in the Bay Area as Founding Chief Technology Officer. At iPierian, she focused the company on applying induced Pluripotent Stem Cell technology to drug discovery for neurodegenerative diseases. Most recently, Berta undertook a new role as Director of the National Center for Personalized Medicine in Israel, located at the Weizmann Institute of Science. The Center will be applying novel technologies in genomics, proteomics and High Throughput Screening to enable and advance Personalized Medicine in Israel.

Meyrav joined Weizmann in 2005 as part of the administrative staff in the department of Neurobiology, where she managed applications for grants, budgets and salaries for students, researchers and employees. She holds a BA from Tel Aviv university in Management and Education. Meyrav joined the INCPM in August 2012 as the center’s administrator. In this role, she oversees all responsibilities of the center’s infrastructure and administration.

Trained as a biotechnology engineer, Daniela finished her studies at Giessen School of Engineering (Fachhochschule) in 1998 before assuming an R&D position at Sequenom, which later went on to become a market leader in the field of commercial mass spectrometry based genotyping. During her time at Sequenom Daniela gradually transitioned from R&D to sales and support, in which capacity she first came to visit the Weizmann Institute.
Daniela installed Israel’s first Sequenom system in Prof. Doron Lancet’s laboratory at the Weizmann Institute in 2001, and soon afterwards opted to stay in Israel and continue her PhD studies in human genetics under the guidance of Prof. Jacqui Beckmann and Prof. Doron Lancet at the Weizmann Institute department of molecular genetics. All the while, Daniela continued working with Sequenom in a support function for the company’s Israel based systems.
Following the completion of her studies in 2007, Daniela was offered to establish the Weizmann Institute’s next-generation sequencing laboratory, which she then headed for four years. She then took a position at Ido Amit’s lab at the department of immunology, splitting her time between her new and old positions. At the Amit laboratory, Daniela devoted her time to specialize in assay development for non-standard sequencing applications and the development of automated high-throughput, low-cost sample preparations.
Daniela was appointed head of the Crown Institute for Genomics at the INCPM in August 2012.

Haim Barr completed his PhD studies in The Technion – Israel Institute of Technology in 2001 and then pursued a career in biotechnology for 11 years. Coming from academic studies in the fields of ubiquitin and phosphatase biology, Haim initially was a research group leader and then lead drug discovery efforts in Proteologics Ltd. In those years, Proteologics successfully transferred from target to small molecule discovery with a unique and automated integration of in vitro ubiquitination assays which has become the backbone of the company’s activities. Subsequently, Haim joined BiolineRx Ltd. where he specialized in recruitment and management of early-phase projects from Israeli and international academic labs for translation into industrial/clinical development. In addition to Haim’s basic science and automation skills, he has been involved in bio-industrial business development for several years, where he served as in-licensing manager in BiolineRx.

Dr. Yishai Levin is a mass spectrometry expert, specializing in protein analysis. He completed his Ph.D. at the University of Cambridge, UK, where he co-developed a blood test for diagnosis of psychiatric disorders. Yishai has been running the Proteomics Unit for two years, working with dozens of investigators on a wide variety of research projects, all relating to proteomic analysis.